Feasibility of Neuroprotective Agent Administration by Prehospital Personnel in an Urban Setting
- 1 August 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 34 (8) , 1918-1922
- https://doi.org/10.1161/01.str.0000080943.59701.0d
Abstract
Background and Purpose— Studies have demonstrated the importance of early stroke treatment. If a neuroprotective agent (NA) clinical trial is successful, the greatest benefit might be attained with early prehospital administration. This study determined the potential reduction in time to treatment of stroke patients when NAs were administered in the prehospital setting. Methods— Twenty-three urban emergency medical services (EMS) agencies participated in this study. Prehospital personnel completed a stroke assessment checklist on any potential stroke victim. The checklist collected clinical inclusion/exclusion criteria for NA administration and event/decision times. Patients meeting the hypothetical clinical inclusion criteria were enrolled into this study. Time data included scene arrival/departure, emergency department (ED) arrival, and estimated time of theoretical NA administration. The reduction in time to stroke treatment was calculated as the difference between the time of ED arrival and the reported time of NA administration. The t test and simple linear regression were used to probe for differences in treatment time reduction between selected subgroups. EMS personnel’s ability to obtain informed consent for theoretical NA administration was calculated. Results— Two hundred twenty-two patients were enrolled in this study; of these, 75 were deemed eligible for hypothetical NA administration and had complete time data. On average, EMS personnel documented the theoretical time of NA administration at 12.04±2.07 minutes before arrival at the ED (17.06±1.74 minutes when the NA was given on scene [n=43]; 6.65±1.14 minutes when the NA was given en route [n=32]). Conclusions— Prehospital NA administration can potentially significantly reduce the time to first intervention in stroke patients.Keywords
This publication has 20 references indexed in Scilit:
- Thrombolysis in Ischaemic Stroke – Present and Future: Role of Combined TherapyCerebrovascular Diseases, 2001
- Intravenous Tissue-Type Plasminogen Activator for Treatment of Acute StrokeJAMA, 2000
- Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing?Trends in Neurosciences, 1999
- Accuracy of paramedic diagnosis of strokeJournal Of Stroke & Cerebrovascular Diseases, 1998
- Multinational Randomised Controlled Trial of Lubeluzole in Acute Ischaemic StrokeCerebrovascular Diseases, 1998
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric StrokeJAMA, 1995
- Randomised, double-blind, placebo-controlled trial of nimodipine in acute strokeThe Lancet, 1990
- An analysis of variance test for normality (complete samples)Biometrika, 1965